| Schedule of Net Loss of Significant Expense |
The following table presents VYNE's segment revenue and significant expenses regularly reviewed by the CODM for the three and six months ended June 30, 2026 and 2025:
| | | | | | | | | | | | | | | | | | | | | | | | | Three Months Ended June 30, | | Six Months Ended June 30, | | (in thousands) | 2026 | | 2025 | | 2026 | | 2025 | | Royalty revenues | $ | 97 | | | $ | 69 | | | $ | 183 | | | $ | 271 | | | Operating expenses | | | | | | | | | Research and development: | | | | | | | | | Repibresib (VYN201) | 42 | | | 2,464 | | | 192 | | | 5,041 | | | VYN202 | 398 | | | 1,667 | | | 592 | | | 4,184 | | | Other segment items* | 348 | | | 750 | | | 821 | | | 1,779 | | | General and administrative | 2,411 | | | 2,730 | | | 5,496 | | | 6,005 | | | Total operating expenses | 3,199 | | | 7,611 | | | 7,101 | | | 17,009 | | | Operating loss | (3,102) | | | (7,542) | | | (6,918) | | | (16,738) | | | Other income, net | 203 | | | 1,795 | | | 434 | | | 2,388 | | | Loss from continuing operations before income taxes | (2,899) | | | (5,747) | | | (6,484) | | | (14,350) | | | Income tax expense | — | | | — | | | — | | | — | | | Loss from continuing operations | (2,899) | | | (5,747) | | | (6,484) | | | (14,350) | | | Loss from discontinued operations, net of income taxes | (108) | | | (8) | | | (108) | | | (16) | | | Net loss | $ | (3,007) | | | $ | (5,755) | | | $ | (6,592) | | | $ | (14,366) | |
*Other segment items relate to research and development expenses that cannot be directly allocated to one specific product candidate, such as employee-related expenses, consulting, quality control, regulatory, and general IP legal expenses.
|